Compare Stocks: NKTX, SLDB, FTH, and OLMA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FTH Sensei Biotherapeutics	$26.33 -2.9%	$32.04	$7.45 ▼ $42.14	$679.46M	-0.29	238,593 shs	29,766 shs
NKTX Nkarta	$2.39 -5.7%	$2.61	$1.70 ▼ $3.72	$170.83M	0.93	719,679 shs	60,452 shs
OLMA Olema Pharmaceuticals	$7.99 -3.2%	$10.37	$6.65 ▼ $36.26	$698.06M	2	1.37 million shs	125,583 shs
SLDB Solid Biosciences	$6.73 -4.6%	$8.78	$3.79 ▼ $11.45	$719.69M	2.47	1.36 million shs	184,315 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FTH Sensei Biotherapeutics	-4.41%	-2.41%	-32.33%	+3.79%	+2,709,999,900.00%
NKTX Nkarta	-1.94%	-5.24%	-13.36%	-25.15%	+18.78%
OLMA Olema Pharmaceuticals	+0.24%	-4.18%	-23.26%	-34.68%	-25.68%
SLDB Solid Biosciences	+3.07%	-3.02%	-31.12%	-36.68%	+19.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FTH Sensei Biotherapeutics	$26.33 -2.9%	$32.04	$7.45 ▼ $42.14	$679.46M	-0.29	238,593 shs	29,766 shs
NKTX Nkarta	$2.39 -5.7%	$2.61	$1.70 ▼ $3.72	$170.83M	0.93	719,679 shs	60,452 shs
OLMA Olema Pharmaceuticals	$7.99 -3.2%	$10.37	$6.65 ▼ $36.26	$698.06M	2	1.37 million shs	125,583 shs
SLDB Solid Biosciences	$6.73 -4.6%	$8.78	$3.79 ▼ $11.45	$719.69M	2.47	1.36 million shs	184,315 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FTH Sensei Biotherapeutics	-4.41%	-2.41%	-32.33%	+3.79%	+2,709,999,900.00%
NKTX Nkarta	-1.94%	-5.24%	-13.36%	-25.15%	+18.78%
OLMA Olema Pharmaceuticals	+0.24%	-4.18%	-23.26%	-34.68%	-25.68%
SLDB Solid Biosciences	+3.07%	-3.02%	-31.12%	-36.68%	+19.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FTH Sensei Biotherapeutics	2.93	Moderate Buy	$56.25	113.68% Upside
NKTX Nkarta	2.86	Moderate Buy	$11.20	369.60% Upside
OLMA Olema Pharmaceuticals	2.77	Moderate Buy	$40.60	408.14% Upside
SLDB Solid Biosciences	2.85	Moderate Buy	$18.69	177.62% Upside

Current Analyst Ratings Breakdown

Latest NKTX, SLDB, FTH, and OLMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	NKTX Nkarta	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/21/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/16/2026	SLDB Solid Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$18.00
9/16/2026	FTH Sensei Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$70.00
9/16/2026	SLDB Solid Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$18.00
9/15/2026	FTH Sensei Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/14/2026	FTH Sensei Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/14/2026	SLDB Solid Biosciences	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
9/14/2026	OLMA Olema Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$48.00 ➝ $30.00
9/14/2026	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
9/9/2026	FTH Sensei Biotherapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$14.74 per share	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	$4.40 per share	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.88 per share	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	$2.28 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FTH Sensei Biotherapeutics	-$21.08M	-$141.65	N/A	N/A	N/A	N/A	-1,012.17%	-175.69%	N/A
NKTX Nkarta	-$104.08M	-$1.57	N/A	N/A	N/A	N/A	-39.64%	-30.45%	11/10/2026 (Estimated)
OLMA Olema Pharmaceuticals	-$162.45M	-$2.12	N/A	N/A	N/A	N/A	-48.26%	-43.04%	11/9/2026 (Estimated)
SLDB Solid Biosciences	-$174.32M	-$1.91	N/A	N/A	N/A	N/A	-71.35%	-60.58%	11/2/2026 (Estimated)

Latest NKTX, SLDB, FTH, and OLMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/2/2026	Q3 2026	SLDB Solid Biosciences	-$0.37	N/A	N/A	N/A	N/A	N/A
8/10/2026	Q2 2026	NKTX Nkarta	-$0.3603	-$0.54	-$0.1797	-$0.54	N/A	N/A
8/10/2026	Q2 2026	OLMA Olema Pharmaceuticals	-$0.5515	-$0.61	-$0.0585	-$0.61	N/A	N/A
8/6/2026	Q2 2026	SLDB Solid Biosciences	-$0.4624	-$0.38	+$0.0824	-$0.38	N/A	N/A
8/4/2026	Q2 2026	FTH Sensei Biotherapeutics	-$5.0450	-$2.84	+$2.2050	-$0.62	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FTH Sensei Biotherapeutics	N/A	19.69	19.69
NKTX Nkarta	N/A	7.98	7.98
OLMA Olema Pharmaceuticals	0.01	8.86	8.86
SLDB Solid Biosciences	N/A	13.82	13.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FTH Sensei Biotherapeutics	10.50%
NKTX Nkarta	80.54%
OLMA Olema Pharmaceuticals	91.78%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
FTH Sensei Biotherapeutics	7.00%
NKTX Nkarta	9.80%
OLMA Olema Pharmaceuticals	12.56%
SLDB Solid Biosciences	2.66%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FTH Sensei Biotherapeutics	29	25.84 million	24.03 million	Not Optionable
NKTX Nkarta	106	71.63 million	64.61 million	Optionable
OLMA Olema Pharmaceuticals	150	87.50 million	76.51 million	Optionable
SLDB Solid Biosciences	121	107.23 million	104.37 million	Optionable

NKTX, SLDB, FTH, and OLMA Headlines

Recent News About These Companies

Solid Biosciences stock fell 1.86 percent on October 2

October 5 at 7:49 AM | ad-hoc-news.deA

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 1, 2026

October 1, 2026 | biospace.comB

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 1, 2026 | globenewswire.com

Solid Biosciences (NASDAQ:SLDB) Stock Price Down 4.7% - Here's Why

September 29, 2026 | marketbeat.com

Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy's Limitations

September 25, 2026 | seekingalpha.com

Solid Biosciences (NASDAQ:SLDB) Trading Down 10% - Time to Sell?

September 23, 2026 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Upgraded to Moderate Buy at Royal Bank Of Canada

September 17, 2026 | marketbeat.com

RBC Capital initiates coverage of Solid Biosciences at outperform

September 17, 2026 | msn.com

Solid Biosciences' Duchenne Muscular Dystrophy Approach, FDA Shift Support Upside, RBC Says

September 16, 2026 | finance.yahoo.com

Solid Biosciences wins new Outperform at RBC on DMD opportunity

September 16, 2026 | seekingalpha.com

Solid Biosciences (NASDAQ:SLDB) Shares Down 6.4% - Time to Sell?

September 15, 2026 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Earns "Buy" Rating from HC Wainwright

September 14, 2026 | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of "Moderate Buy" by Analysts

September 14, 2026 | marketbeat.com

Solid Biosciences (SLDB) Gets a Buy from Citi

September 12, 2026 | theglobeandmail.com

Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 10, 2026 | seekingalpha.com

243,154 Shares in Solid Biosciences Inc. $SLDB Purchased by Bank of New York Mellon Corp

September 8, 2026 | marketbeat.com

Solid Biosciences to Participate at Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Solid Biosciences (SLDB)

August 8, 2026 | theglobeandmail.com

Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 6, 2026 | finance.yahoo.com

Analysts Conflicted on These Healthcare Names: Nuvalent (NUVL) and Solid Biosciences (SLDB)

July 7, 2026 | theglobeandmail.com

Solid Biosciences: The Bull Case Is No Longer Just Duchenne

July 2, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX, SLDB, FTH, and OLMA Company Descriptions

Sensei Biotherapeutics NASDAQ:FTH

$26.32 -0.78 (-2.86%)

As of 10:31 AM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Nkarta NASDAQ:NKTX

$2.38 -0.15 (-5.73%)

As of 10:31 AM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Olema Pharmaceuticals NASDAQ:OLMA

$7.99 -0.26 (-3.15%)

As of 10:32 AM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Solid Biosciences NASDAQ:SLDB

$6.73 -0.33 (-4.63%)

As of 10:32 AM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NKTX, SLDB, FTH, and OLMA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NKTX, SLDB, FTH, and OLMA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NKTX, SLDB, FTH, and OLMA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX, SLDB, FTH, and OLMA Company Descriptions

Sensei Biotherapeutics NASDAQ:FTH

Nkarta NASDAQ:NKTX

Olema Pharmaceuticals NASDAQ:OLMA

Solid Biosciences NASDAQ:SLDB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NKTX, SLDB, FTH, and OLMA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NKTX, SLDB, FTH, and OLMA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NKTX, SLDB, FTH, and OLMA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX, SLDB, FTH, and OLMA Company Descriptions

Sensei Biotherapeutics NASDAQ:FTH

Nkarta NASDAQ:NKTX

Olema Pharmaceuticals NASDAQ:OLMA

Solid Biosciences NASDAQ:SLDB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools